Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-01

Study Completion Date

2021-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized controlled clinical trial on using oral ivermectin in COVID-19 prophylaxis supplying the drug to close contacts of confirmed cases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ivermectin to Prevent Hospitalizations in COVID-19

NCT04529525

Covid19

COMPLETED PHASE2/PHASE3

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19

NCT04834115

Covid19 Coronavirus Infection

UNKNOWN PHASE3

A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention

NCT05305560

COVID-19

COMPLETED PHASE2

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

NCT04407507

COVID-19

COMPLETED PHASE2

COVidIVERmectin: Ivermectin for Treatment of Covid-19

NCT04438850

Covid19

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, and controlled clinical trial that aims to evaluate the use of oral ivermectin in COVID-19 prophylaxis. The study has two arms in a relationship of 2:1: Experimental Group (EG n=500) and Placebo Group (CG n=250).

The sample size was calculated by applying a two-proportion comparison test. Type of two-sided test, 95% confidence or safety level (1-α), 95% statistical power, 75% P1 (proportion in the placebo group), 65% P2 (proportion in the new treatment or intervention group), size sample without adjustment (n = 543), 25% expected proportion of losses, n= 724 sample adjusted for losses.

The hypothesis of the study is that treatment with ivermectin may decrease the chance of occurrence/progress of clinical manifestations and onset of severe disease. Whereas control of the contagion on the first days of development of the disease, this treatment with ivermectin in suspected cases of COVID-19 (by epidemiological nexus) would contribute to the control of contagion at the first part of the infection, even in the absence of symptoms.

Categorical variables will be represented with frequencies and proportions, while continuous quantitative variables will be expressed as mean ± standard deviation (SD) or as median and interquartile range (IQR). The proportions will be compared using Pearson's Chi-square test or Fisher's exact test as appropriate, and continuous quantitative variables with Student's t test. The estimation of the efficacy of intensive treatment with Ivermectin will be calculated using Kaplan-Meier curves and the differences will be analyzed by means of the log-rank test. The risk will be calculated as a ratio of advantages for Intensive treatment with Ivermectin (Odds Ratio, OR) with its 95% confidence intervals (95% CI). A value of p \<0.05 will be considered significant. Analyzes will be performed using Stata 11.2 software.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled. Experimental and Control Group in relationship of 2:1

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Double-Blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group

The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care

Group Type EXPERIMENTAL

Ivermectin

Intervention Type DRUG

0,6mg/kg of weight orally on days 1 and 7

Control Group

The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

A substance with similar physical characteristics as ivermectin, without the active drug ingredient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivermectin

0,6mg/kg of weight orally on days 1 and 7

Intervention Type DRUG

Placebo

A substance with similar physical characteristics as ivermectin, without the active drug ingredient

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Iver

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years either sex
* Women of childbearing age with a negative pregnancy test
* In close contact group or epidemiological nexus of a positive COVID-19 case
* Able to understand and grant informed consent
* Real-time - polymerase chain reaction test with a negative result

Exclusion Criteria

* Known hypersensitivity or allergy to any component of the drug under evaluation
* Age under 18 years
* Use of immunosuppressants (including systemic corticosteroids) in the last 30 days
* Pregnant or lactating
* Patients with other acute infectious diseases
* Patients with autoimmune disease and/or chronic decompensated diseases
* Who have received a vaccine for COVID-19 (1/2 dose) or that have taken ivermectin (prior to 30 days of the study) or who are participating in another COVID-19 prophylaxis study

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes